ID

38121

Descripción

AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL); ODM derived from: https://clinicaltrials.gov/show/NCT01791985

Link

https://clinicaltrials.gov/show/NCT01791985

Palabras clave

Versiones (1)
  1. 19/9/19 19/9/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

19 de septiembre de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Breast Cancer NCT01791985

Inglés

Eligibility Breast Cancer NCT01791985

1 formularios  
Criteria
Descripción

Criteria

written informed consent and ability to comply with study protocol
Descripción

Informed Consent | Protocol Compliance

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2]
C0525058
aged ≥ 25 years of age
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
post menopausal women with histological confirmation of breast cancer with documented positive oestrogen receptor status (er+) of primary or metastatic tumour tissue
Descripción

Postmenopausal state | Breast Carcinoma | Tissue sample Primary tumor Estrogen receptor positive | Tissue sample Neoplasm Metastasis Estrogen receptor positive

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0678222
UMLS CUI [3,1]
C0475358
UMLS CUI [3,2]
C0677930
UMLS CUI [3,3]
C0279754
UMLS CUI [4,1]
C0475358
UMLS CUI [4,2]
C0027627
UMLS CUI [4,3]
C0279754
ecog performance status 0-1 and minimum life expectancy of 12 weeks
Descripción

ECOG performance status | Life Expectancy Minimum

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
UMLS CUI [2,1]
C0023671
UMLS CUI [2,2]
C1524031
fulfils criteria for previous treatment of breast cancer:
Descripción

Prior Therapy Breast Carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0678222
safety run-in: relapse during a single regimen of adjuvant endocrine therapy with either anastrozole or letrozole or
Descripción

Safety Run-in | Relapse | Hormone Therapy Adjuvant | anastrozole | letrozole

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0036043
UMLS CUI [1,2]
C3274438
UMLS CUI [2]
C0035020
UMLS CUI [3,1]
C0279025
UMLS CUI [3,2]
C1522673
UMLS CUI [4]
C0290883
UMLS CUI [5]
C0246421
progression during first line endocrine therapy with anastrozole or letrozole for advanced breast cancer phase iia: progressing or progression at some point during breast cancer treatment on endocrine therapy with a non-steroidal ai*
Descripción

Disease Progression | First line Hormone Therapy Advanced breast cancer | anastrozole | letrozole | Breast Cancer Therapeutic Procedure | Hormone Therapy | Non-Steroidal Aromatase Inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2,1]
C1708063
UMLS CUI [2,2]
C0279025
UMLS CUI [2,3]
C3495917
UMLS CUI [3]
C0290883
UMLS CUI [4]
C0246421
UMLS CUI [5]
C1511300
UMLS CUI [6]
C0279025
UMLS CUI [7]
C1518386
co-administration of a targeted agent with the non-steroidal ai is permitted providing all toxicities have recovered to ctcae grade 1 or below.
Descripción

Targeted Therapy Non-Steroidal Aromatase Inhibitor | Toxicity Recovery CTCAE Grades

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2985566
UMLS CUI [1,2]
C1518386
UMLS CUI [2,1]
C0600688
UMLS CUI [2,2]
C2004454
UMLS CUI [2,3]
C1516728
prior chemotherapy in the advanced and adjuvant setting is permitted.
Descripción

Prior Chemotherapy Advanced disease | Prior Chemotherapy Adjuvant

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1514457
UMLS CUI [1,2]
C0679246
UMLS CUI [2,1]
C1514457
UMLS CUI [2,2]
C1522673
prior treatment with exemestane with or without everolimus is permitted.
Descripción

Prior Therapy | exemestane | everolimus | Everolimus Absent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2]
C0851344
UMLS CUI [3]
C0541315
UMLS CUI [4,1]
C0541315
UMLS CUI [4,2]
C0332197
*anastrozole or letrozole does not have to be the most recent therapy
Descripción

Prior Therapy | anastrozole | letrozole

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2]
C0290883
UMLS CUI [3]
C0246421
safety run-in: at least 1 lesion (measurable/non measurable) that can be accurately assessed by ct/mri/plain x-ray at baseline and follow-up phase iia: at least 1 measurable lesion ≥ 10mm in longest diameter (or ≥ 15mm in the short axis for nodal disease) at baseline that can be accurately assessed by ct/mri at baseline and follow up. patients with bone only metastatic cancer must have a lytic or mixed lytic-blastic lesion that can be accurately assessed by ct or mri.
Descripción

Safety Run-in | Measurable lesion Quantity CT | Non-Measurable Lesion Quantity CT | Measurable lesion Quantity MRI | Non-Measurable Lesion Quantity MRI | Measurable lesion Quantity Plain x-ray | Non-Measurable Lesion Quantity Plain x-ray | Follow-up | Measurable lesion Quantity Longest Diameter | Measurable lesion Short axis Disorder of lymph node | Secondary malignant neoplasm of bone | Lytic lesion CT | Lytic lesion MRI | Other Coding

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0036043
UMLS CUI [1,2]
C3274438
UMLS CUI [2,1]
C1513041
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C0040405
UMLS CUI [3,1]
C1334988
UMLS CUI [3,2]
C1265611
UMLS CUI [3,3]
C0040405
UMLS CUI [4,1]
C1513041
UMLS CUI [4,2]
C1265611
UMLS CUI [4,3]
C0024485
UMLS CUI [5,1]
C1334988
UMLS CUI [5,2]
C1265611
UMLS CUI [5,3]
C0024485
UMLS CUI [6,1]
C1513041
UMLS CUI [6,2]
C1265611
UMLS CUI [6,3]
C1306645
UMLS CUI [7,1]
C1334988
UMLS CUI [7,2]
C1265611
UMLS CUI [7,3]
C1306645
UMLS CUI [8]
C3274571
UMLS CUI [9,1]
C1513041
UMLS CUI [9,2]
C1265611
UMLS CUI [9,3]
C0552406
UMLS CUI [10,1]
C1513041
UMLS CUI [10,2]
C0522488
UMLS CUI [10,3]
C0272394
UMLS CUI [11]
C0153690
UMLS CUI [12,1]
C0221204
UMLS CUI [12,2]
C0040405
UMLS CUI [13,1]
C0221204
UMLS CUI [13,2]
C0024485
UMLS CUI [14]
C3846158
adequate haematological, hepatic and renal function
Descripción

Hematologic function | Liver function | Renal function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232741
UMLS CUI [3]
C0232804
phase iia: mandatory provision of tumour biopsy for assessment of oncology biomarkers
Descripción

Tumor Biopsy | Assessment Tumor Biomarkers

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0027651
UMLS CUI [1,2]
C0005558
UMLS CUI [2,1]
C1516048
UMLS CUI [2,2]
C0041366
safety run-in: study entry must be preceded by a minimum of 21 days of anastrozole or letrozole treatment
Descripción

Safety Run-in | Pre treatment | anastrozole | letrozole

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0036043
UMLS CUI [1,2]
C3274438
UMLS CUI [2]
C2709094
UMLS CUI [3]
C0290883
UMLS CUI [4]
C0246421
phase iia: no restriction to duration of anastrozole or letrozole treatment prior to study entry.
Descripción

Duration of treatment Without Restriction | anastrozole | letrozole

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0444921
UMLS CUI [1,2]
C0332288
UMLS CUI [1,3]
C0443288
UMLS CUI [2]
C0290883
UMLS CUI [3]
C0246421
Volver a la parte superior de la página

Similar models

Eligibility Breast Cancer NCT01791985

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Informed Consent | Protocol Compliance
Item
written informed consent and ability to comply with study protocol
boolean
C0021430 (UMLS CUI [1])
C0525058 (UMLS CUI [2])
Age
Item
aged ≥ 25 years of age
boolean
C0001779 (UMLS CUI [1])
Postmenopausal state | Breast Carcinoma | Tissue sample Primary tumor Estrogen receptor positive | Tissue sample Neoplasm Metastasis Estrogen receptor positive
Item
post menopausal women with histological confirmation of breast cancer with documented positive oestrogen receptor status (er+) of primary or metastatic tumour tissue
boolean
C0232970 (UMLS CUI [1])
C0678222 (UMLS CUI [2])
C0475358 (UMLS CUI [3,1])
C0677930 (UMLS CUI [3,2])
C0279754 (UMLS CUI [3,3])
C0475358 (UMLS CUI [4,1])
C0027627 (UMLS CUI [4,2])
C0279754 (UMLS CUI [4,3])
ECOG performance status | Life Expectancy Minimum
Item
ecog performance status 0-1 and minimum life expectancy of 12 weeks
boolean
C1520224 (UMLS CUI [1])
C0023671 (UMLS CUI [2,1])
C1524031 (UMLS CUI [2,2])
Prior Therapy Breast Carcinoma
Item
fulfils criteria for previous treatment of breast cancer:
boolean
C1514463 (UMLS CUI [1,1])
C0678222 (UMLS CUI [1,2])
Safety Run-in | Relapse | Hormone Therapy Adjuvant | anastrozole | letrozole
Item
safety run-in: relapse during a single regimen of adjuvant endocrine therapy with either anastrozole or letrozole or
boolean
C0036043 (UMLS CUI [1,1])
C3274438 (UMLS CUI [1,2])
C0035020 (UMLS CUI [2])
C0279025 (UMLS CUI [3,1])
C1522673 (UMLS CUI [3,2])
C0290883 (UMLS CUI [4])
C0246421 (UMLS CUI [5])
Disease Progression | First line Hormone Therapy Advanced breast cancer | anastrozole | letrozole | Breast Cancer Therapeutic Procedure | Hormone Therapy | Non-Steroidal Aromatase Inhibitor
Item
progression during first line endocrine therapy with anastrozole or letrozole for advanced breast cancer phase iia: progressing or progression at some point during breast cancer treatment on endocrine therapy with a non-steroidal ai*
boolean
C0242656 (UMLS CUI [1])
C1708063 (UMLS CUI [2,1])
C0279025 (UMLS CUI [2,2])
C3495917 (UMLS CUI [2,3])
C0290883 (UMLS CUI [3])
C0246421 (UMLS CUI [4])
C1511300 (UMLS CUI [5])
C0279025 (UMLS CUI [6])
C1518386 (UMLS CUI [7])
Targeted Therapy Non-Steroidal Aromatase Inhibitor | Toxicity Recovery CTCAE Grades
Item
co-administration of a targeted agent with the non-steroidal ai is permitted providing all toxicities have recovered to ctcae grade 1 or below.
boolean
C2985566 (UMLS CUI [1,1])
C1518386 (UMLS CUI [1,2])
C0600688 (UMLS CUI [2,1])
C2004454 (UMLS CUI [2,2])
C1516728 (UMLS CUI [2,3])
Prior Chemotherapy Advanced disease | Prior Chemotherapy Adjuvant
Item
prior chemotherapy in the advanced and adjuvant setting is permitted.
boolean
C1514457 (UMLS CUI [1,1])
C0679246 (UMLS CUI [1,2])
C1514457 (UMLS CUI [2,1])
C1522673 (UMLS CUI [2,2])
Prior Therapy | exemestane | everolimus | Everolimus Absent
Item
prior treatment with exemestane with or without everolimus is permitted.
boolean
C1514463 (UMLS CUI [1])
C0851344 (UMLS CUI [2])
C0541315 (UMLS CUI [3])
C0541315 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Prior Therapy | anastrozole | letrozole
Item
*anastrozole or letrozole does not have to be the most recent therapy
boolean
C1514463 (UMLS CUI [1])
C0290883 (UMLS CUI [2])
C0246421 (UMLS CUI [3])
Safety Run-in | Measurable lesion Quantity CT | Non-Measurable Lesion Quantity CT | Measurable lesion Quantity MRI | Non-Measurable Lesion Quantity MRI | Measurable lesion Quantity Plain x-ray | Non-Measurable Lesion Quantity Plain x-ray | Follow-up | Measurable lesion Quantity Longest Diameter | Measurable lesion Short axis Disorder of lymph node | Secondary malignant neoplasm of bone | Lytic lesion CT | Lytic lesion MRI | Other Coding
Item
safety run-in: at least 1 lesion (measurable/non measurable) that can be accurately assessed by ct/mri/plain x-ray at baseline and follow-up phase iia: at least 1 measurable lesion ≥ 10mm in longest diameter (or ≥ 15mm in the short axis for nodal disease) at baseline that can be accurately assessed by ct/mri at baseline and follow up. patients with bone only metastatic cancer must have a lytic or mixed lytic-blastic lesion that can be accurately assessed by ct or mri.
boolean
C0036043 (UMLS CUI [1,1])
C3274438 (UMLS CUI [1,2])
C1513041 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0040405 (UMLS CUI [2,3])
C1334988 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0040405 (UMLS CUI [3,3])
C1513041 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0024485 (UMLS CUI [4,3])
C1334988 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
C0024485 (UMLS CUI [5,3])
C1513041 (UMLS CUI [6,1])
C1265611 (UMLS CUI [6,2])
C1306645 (UMLS CUI [6,3])
C1334988 (UMLS CUI [7,1])
C1265611 (UMLS CUI [7,2])
C1306645 (UMLS CUI [7,3])
C3274571 (UMLS CUI [8])
C1513041 (UMLS CUI [9,1])
C1265611 (UMLS CUI [9,2])
C0552406 (UMLS CUI [9,3])
C1513041 (UMLS CUI [10,1])
C0522488 (UMLS CUI [10,2])
C0272394 (UMLS CUI [10,3])
C0153690 (UMLS CUI [11])
C0221204 (UMLS CUI [12,1])
C0040405 (UMLS CUI [12,2])
C0221204 (UMLS CUI [13,1])
C0024485 (UMLS CUI [13,2])
C3846158 (UMLS CUI [14])
Hematologic function | Liver function | Renal function
Item
adequate haematological, hepatic and renal function
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Tumor Biopsy | Assessment Tumor Biomarkers
Item
phase iia: mandatory provision of tumour biopsy for assessment of oncology biomarkers
boolean
C0027651 (UMLS CUI [1,1])
C0005558 (UMLS CUI [1,2])
C1516048 (UMLS CUI [2,1])
C0041366 (UMLS CUI [2,2])
Safety Run-in | Pre treatment | anastrozole | letrozole
Item
safety run-in: study entry must be preceded by a minimum of 21 days of anastrozole or letrozole treatment
boolean
C0036043 (UMLS CUI [1,1])
C3274438 (UMLS CUI [1,2])
C2709094 (UMLS CUI [2])
C0290883 (UMLS CUI [3])
C0246421 (UMLS CUI [4])
Duration of treatment Without Restriction | anastrozole | letrozole
Item
phase iia: no restriction to duration of anastrozole or letrozole treatment prior to study entry.
boolean
C0444921 (UMLS CUI [1,1])
C0332288 (UMLS CUI [1,2])
C0443288 (UMLS CUI [1,3])
C0290883 (UMLS CUI [2])
C0246421 (UMLS CUI [3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial